Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model. 1993

A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
Third Department of Internal Medicine, Nagasaki University School of Medicine, Japan.

Numerous studies have shown that E-4031 generally prolongs the atrial effective refractory period (AERP) without affecting cardiac conduction. The effects of E-4031 on AERP and cardiac conduction at short cycle lengths (CLs) close to the AERP were measured in 12 dogs with sterile pericarditis. Three pairs of electrodes were sutured at three sites in the atria 4 days after the model was created. We measured AERP and maximum conduction delay (MCD) after 8 beats train at CLs of 400, 300, 200 and 150 ms before and during continuous infusion of E-4031 (0.1 microgram/kg/min) that followed an initial dose of 10 micrograms/kg/min/5 min. E-4031 interrupted sustained atrial flutter (AF) (> or = 10 min) in 4 of 5 episodes and atrial fibrillation (> or = 10 min) in 4 of 4. The CL of AF defined as a rapid atrial rhythm (rate > or = 240 beats/min) in five episodes studied in the sterile pericarditis model was significantly (p < 0.005) prolonged from 120 +/- 8 to 160 +/- 17 ms. There were significant (p < 0.005) increases in AERP at each CL, and prolongation of AERP was 39 +/- 18, 31 +/- 14, 23 +/- 14, and 16 +/- 14 ms at CL 400, 300, 200, and 150 ms, respectively. E-4031 produced less prolongation of AERP at short pacing CLs and had no effect on conduction time during atrial rapid pacing at CLs > 150 ms. E-4031 did not prolong MCD at CL 400 ms, but did prolong MCD at CLs of 300, 200, and 150 ms, despite prolongation of AERP.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008955 Models, Cardiovascular Theoretical representations that simulate the behavior or activity of the cardiovascular system, processes, or phenomena; includes the use of mathematical equations, computers and other electronic equipment. Cardiovascular Model,Cardiovascular Models,Model, Cardiovascular
D010493 Pericarditis Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS. Pleuropericarditis
D010880 Piperidines A family of hexahydropyridines.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006329 Heart Conduction System An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart. Conduction System, Heart,Conduction Systems, Heart,Heart Conduction Systems,System, Heart Conduction,Systems, Heart Conduction
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
July 1993, Cardiovascular research,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
July 2001, Journal of cardiovascular pharmacology and therapeutics,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
June 1990, The Journal of pharmacology and experimental therapeutics,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
March 1994, Journal of cardiovascular pharmacology,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
September 1996, Journal of cardiovascular electrophysiology,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
February 2002, Circulation journal : official journal of the Japanese Circulation Society,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
August 2003, Journal of cardiovascular electrophysiology,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
April 1997, Journal of cardiovascular pharmacology,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
July 1993, Journal of cardiovascular pharmacology,
A Shimizu, and M Kaibara, and O A Centurion, and G Kapuku, and T Hirata, and M Fukatani, and K Yano, and K Hashiba
June 1992, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!